Cisplatin Differentially Damages Mammalian Vestibular End Organs

Area of Science:

• Ototoxicology
• Neuroscience
• Vestibular System Research

Background:

• Cisplatin is a vital chemotherapy agent with known cochleotoxicity.
• The vestibulotoxic effects of cisplatin are not well understood.
• Previous research established a multicycle cisplatin mouse model for hearing loss.

Purpose of the Study:

• To investigate the functional and morphological effects of cisplatin on the vestibular periphery.
• To characterize cisplatin's impact on balance function in a validated mouse model.
• To compare mouse findings with human temporal bone histopathology.

Main Methods:

• Mice received multiple cycles of cisplatin, followed by vestibular sensory evoked potential testing.
• Vestibulo-ocular reflex testing and single-unit recordings were performed post-treatment.
• Morphological analysis of vestibular end organs (utricle, saccule, semicircular canals) was conducted.
• Human temporal bone histopathology was reviewed for correlation.

Main Results:

• Cisplatin elevated vestibular sensory evoked potential thresholds, worsening over time.
• Otolith afferent responses showed decreased regularity and precision.
• Saccular hair cell counts were significantly reduced, unlike the utricle or semicircular canals.
• Human temporal bone data showed concordance with saccular degeneration.

Conclusions:

• Cisplatin adversely and differentially impacts vestibular end organs, with the saccule being uniquely susceptible.
• Vestibular dysfunction may progress even after cisplatin treatment cessation.
• Monitoring otolith function is recommended for patients undergoing cisplatin therapy.